Entresto(sacubitril)
Entresto, Neparvis, Sacubitril / Valsartan (sacubitril) is a small molecule pharmaceutical. Sacubitril was first approved as Entresto on 2015-07-07. It has been approved in Europe to treat heart failure.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Combinations
Entresto, Sacubitril valsartan
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| entresto | New Drug Application | 2025-08-12 |
| sacubitril and valsartan | ANDA | 2025-07-29 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SACUBITRIL / VALSARTAN, ENTRESTO, NOVARTIS PHARMS CORP | |||
| 2024-02-16 | M-82 | ||
HCPCS
No data
Clinical
Clinical Trials
204 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | 7 | 13 | 13 | 15 | 47 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | 1 | 1 | 1 | 3 |
| Chagas disease | D014355 | EFO_0008559 | B57 | — | — | — | 1 | — | 1 |
| Left ventricular dysfunction | D018487 | — | — | — | — | — | 1 | — | 1 |
| Mitral valve insufficiency | D008944 | — | — | — | — | — | 1 | — | 1 |
| Ventricular dysfunction | D018754 | — | — | — | — | — | 1 | — | 1 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 10 | 9 | — | 2 | 21 |
| Essential hypertension | D000075222 | — | I10 | — | 4 | 4 | — | 1 | 9 |
| Systolic murmurs | D054160 | — | R01.1 | — | 1 | 1 | — | 1 | 3 |
| Renal insufficiency | D051437 | — | N19 | 1 | 1 | 1 | — | — | 3 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 2 | — | — | 2 |
| Infarction | D007238 | EFO_0009463 | — | — | — | 2 | — | — | 2 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | 1 | — | — | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | — | — | — | 2 |
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | 1 | — | — | — | 1 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | 1 | — | — | — | 1 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | — | — | — | 1 |
| Isolated systolic hypertension | D000092244 | — | — | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Male breast neoplasms | D018567 | — | — | — | 1 | — | — | — | 1 |
| Body weight | D001835 | EFO_0004338 | — | — | 1 | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sacubitril |
| INN | sacubitril |
| Description | Sacubitril is a member of biphenyls. |
| Classification | Small molecule |
| Drug class | endopeptidase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 149709-62-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3137301 |
| ChEBI ID | — |
| PubChem CID | 9811834 |
| DrugBank | DB09292 |
| UNII ID | 17ERJ0MKGI (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Entresto – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Sacubitril
+
Valsartan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,216 documents
View more details
Safety
Black-box Warning
Black-box warning for: Entresto, Sacubitril and valsartan
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
111,983 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use